Royalty Pharma

RPRX · NASDAQ

$62.25+$1.98 (+3.29%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $60.27

RPRX analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $64.49 (+3.6% upside)

Low: $46.46
Now: $62.25
High: $73.50

Upgrades and downgrades

The latest rating actions, newest first

RPRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Morgan Stanley	Oct 7, 2026	Maintains	Overweight	$65.00 → $67.00	63%
TD Cowen	Sep 8, 2026	Maintains	Buy	$65.00 → $68.00	33%
JP Morgan	Aug 7, 2026	Maintains	Overweight	$58.00 → $62.00	65%
TD Cowen	Jul 13, 2026	Maintains	Buy	$50.00 → $65.00	76%
Citigroup	May 7, 2026	Maintains	Buy	$50.00 → $66.00	60%
JP Morgan	May 7, 2026	Maintains	Overweight	$50.00 → $58.00	65%
UBS	Apr 21, 2026	Maintains	Buy	$51.00 → $57.00	56%
Morgan Stanley	Apr 10, 2026	Maintains	Overweight	$61.00 → $63.00	63%
UBS	Jan 30, 2026	Upgrade	Neutral → Buy	$38.00 → $49.00	56%
Citigroup	Jan 27, 2026	Maintains	Buy	$48.00 → $50.00	60%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.